SCHEMBL9963364

SCHEMBL9963364

Cc1c(CNC(C)C)cnn1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
MAPK1 P28482 1/20 0.35
MC4R P32245 1/20 0.34
TP53 P04637 2/20 0.33
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KAT2B Q92831 1/20 0.33
ADRA2C P18825 1/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC3 O15379 1/20 0.33
ROCK2 O75116 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 2/20 0.32
HSD17B10 Q99714 1/20 0.32
HIF1A Q16665 1/20 0.32
POLB P06746 1/20 0.32
BRD4 O60885 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4207236 0.79 MAPK1 (0.38) MAPK1TP53MAPTSMN1; SMN2KAT2B
SCHEMBL22722100 0.76 MAPT (0.42) MAPK1TP53MAPTSMN1; SMN2HDAC1
SCHEMBL2259433 0.76 HDAC1 (0.37) MAPK1MC4RTP53MAPTSMN1; SMN2
SCHEMBL12414776 0.75 KDM4E (0.36) MAPK1MAPTSMN1; SMN2ALDH1A1KDM4E
SCHEMBL17788642 0.74 MAPK1 (0.39) MAPK1TP53MAPTSMN1; SMN2HDAC1
SCHEMBL4207232 0.73 HDAC1 (0.36) MAPK1TP53MAPTSMN1; SMN2KAT2B
SCHEMBL13736669 0.73 MAPT (0.47) MAPK1TP53MAPTSMN1; SMN2HDAC1
SCHEMBL14184717 0.72 KDM4E (0.34) OPRM1OPRD1MAPK1MAPTALDH1A1
SCHEMBL16136320 0.71 SETDB1 (0.44) MAPK1TP53MAPTSMN1; SMN2ROCK2
SCHEMBL8342654 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160151335-A1 METHODS OF MODULATING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2016-06-02 US disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160151335-A1 METHODS OF MODULATING CFTR ACTIVITY CFTR, HSP90B1, SERPINB1 OPRM1 3476/4885OPRD1 2149/4885MAPK1 3176/4885
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 OPRM1 52/4885OPRD1 10/4885MAPK1 1851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.